Figure 6. Adjusted HR and 95% CI from multivariable models evaluating CMV antigenemia before day 100 as a risk factor for nonrelapse mortality at 1 year and overall mortality at 1 year. Covariates: 1, disease risk (low, standard, or high); 2, cytogenetic risk (low, intermediate, or high); 3, age (0-40 years vs ≥40 years); 4, cell source (bone marrow vs PBSC); 5, HLA matching (matched vs mismatched); 6, conditioning regimen (reduced intensity vs myeloablative); 7, donor and recipient CMV serostatus (D−/R−, D+/R−, D−/R+, D+/R+); 8, GVHD prophylaxis (calcineurin inhibitor alone, calcineurin + methotrexate, or calcineurin inhibitor + mycophenolate mofetil); 9, acute GVHD (grades 3-4 vs 0-2); 10, transplant year (January 1995 to November 1998, December 1998 to May 2002, or June 2002 December 2005).
Figure 6

Adjusted HR and 95% CI from multivariable models evaluating CMV antigenemia before day 100 as a risk factor for nonrelapse mortality at 1 year and overall mortality at 1 year. Covariates: 1, disease risk (low, standard, or high); 2, cytogenetic risk (low, intermediate, or high); 3, age (0-40 years vs ≥40 years); 4, cell source (bone marrow vs PBSC); 5, HLA matching (matched vs mismatched); 6, conditioning regimen (reduced intensity vs myeloablative); 7, donor and recipient CMV serostatus (D−/R−, D+/R−, D−/R+, D+/R+); 8, GVHD prophylaxis (calcineurin inhibitor alone, calcineurin + methotrexate, or calcineurin inhibitor + mycophenolate mofetil); 9, acute GVHD (grades 3-4 vs 0-2); 10, transplant year (January 1995 to November 1998, December 1998 to May 2002, or June 2002 December 2005).

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal